Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Innate Pharma stock tumbles after phase 1 trial data (Investing.com) +++ INNATE PHARMA Aktie -4,85%

INNATE PHARMA Aktie

 >INNATE PHARMA Aktienkurs 
1.02 EUR    -16.9%    (TradegateBSX)
Ask: 0.999 EUR / 1002 Stück
Bid: 0.976 EUR / 1025 Stück
Tagesumsatz: 13651 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>INNATE PHARMA Performance
1 Woche: -6,3%
1 Monat: -3,9%
3 Monate: -31,4%
6 Monate: -29,2%
1 Jahr: -21,1%
laufendes Jahr: -22,3%
>INNATE PHARMA Aktie
Name:  INNATE PHARMA EO -,05
Land:  Frankreich
Sektor:  Gesundheit
ISIN/ Wkn:  FR0010331421 / A0LCUJ
Symbol/ Ticker:  IDD (Frankfurt)
Kürzel:  FRA:IDD, ETR:IDD, IDD:GR
Index:  -
Profil:  Innate Pharma S.A. is a global, clinical-stage biotechnology company specializing in oncology-focused immunotherapies that harness the innate immune system to combat cancer. Founded in 1999 by pioneers in innate immunity, the company leverages expert..
>Volltext..
Marktkapitalisierung:  138.06 Mio. EUR
Unternehmenswert:  147.37 Mio. EUR
Umsatz:  4.39 Mio. EUR
EBITDA:  -53.91 Mio. EUR
Nettogewinn:  -49.29 Mio. EUR
Gewinn je Aktie:  -0.53 EUR
Schulden:  20.99 Mio. EUR
Liquide Mittel:  6.71 Mio. EUR
Operativer Cashflow:  -43.88 Mio. EUR
Bargeldquote:  0.33
Umsatzwachstum:  -29.48%
Gewinnwachstum:  -3.05%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  INNATE PHARMA
Letzte Datenerhebung:  18.11.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 111.7 Mio. St.
Frei handelbar: 79.11%
Leerverk. Aktien: -
Rückkaufquote: -0.04%
Mitarbeiter: 163
Umsatz/Mitarb.: 0.02 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 397.42%
Bewertung:
KGV: -
KGV lG: -
KUV: 27.5
KBV: -
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -1121.63%
Operative Marge: -1257.13%
Managementeffizenz:
Gesamtkaprendite: -74.35%
Eigenkaprendite: -
>Peer Group
Gesundheit, Antikörper- Behandlung, Onkologie/ Krebs- Behandlung
 
18.11.26 - 17:36
Innate Pharma-Aktie bricht nach Phase-1-Studiendaten ein (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
18.11.26 - 17:27
Innate Pharma stock tumbles after phase 1 trial data (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.11.26 - 21:01
Innate Pharma auf der Stifel Healthcare Conference: Onkologie-Pipeline steuert auf entscheidende Wendepunkte zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.26 - 12:00
Innate Pharma reports €96.8M in cash, outlines key 2027 pipeline milestones (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.11.26 - 07:03
Innate Pharma Reports Third Quarter 2026 Business and Financial Update (Business Wire)
 
Phase 1 dose-escalation data for Nectin-4 ADC IPH4502 to be presented at ENA 2026 on November 18, followed by a webcast and in-person event Lacutamab, partnered with Sobi, progressing toward first patient dosing in the Phase 3 TELLOMAK-3 trial in Q1 2027, with an FDA accelerated approval filing planned in Sézary syndrome in H2 2027 AstraZeneca-led PACIFIC-9 Phase 3 trial of durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC, readout expected in the first half of 2027 Cash position of €96.8 million1 as of September 30, 2026; anticipated cash horizon until the end of Q1 2028 Conference call to be held today at 2:00 p.m. CET / 8:00 a.m. ET MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine months ended September 30, 2026. “As we approach year-end, our strengthened cash position enables us to work towards executing the ...
20.10.26 - 07:03
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update (Business Wire)
 
MARSEILLE, France--(BUSINESS WIRE)--#Biotech--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8 a.m. ET, to provide a business and financial update for the third quarter of 2026. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Markus Jensen, Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Stéphanie Cornen, Vice President, Investor Relations and Communications Frédéric Lombard, Senior Vice President, Chief Financial Officer Event details Date and time: November 5, 2026 at 2:00 p.m. CET / 8:00 a.m. ET Webcast link: Click here Conference call link: Click here This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following ...
23.09.26 - 19:45
Innate Pharma (IPHA) Upgraded to Buy: Here′s What You Should Know (Zacks)
 
Innate Pharma (IPHA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy)....
18.09.26 - 05:12
Innate Pharma (IPHA) Q2 2026 Earnings Call Transcript (Fool)
 
Lacutamab advances toward accelerated approval as ADC pipeline expands....
17.09.26 - 14:48
Innate Pharma übertrifft Q2-Prognosen, doch die Aktie gibt nach (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
17.09.26 - 07:21
Innate Pharma gives H1 results (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.09.26 - 07:06
Innate Pharma Reports First Half 2026 Business Update and Financial Results (Business Wire)
 
New strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing completed to primarily support IPH4502 and preclinical ADC portfolio IPH4502 Phase 1 dose escalation and cohort enrichment enrollment completed, with initial data to be presented at ENA 2026 PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected in H2 2026 Cash position of €21.4 million1 as of June 30, 2026 Anticipated cash horizon until the end of Q1 2028, taking into account the initial payment of $75 million expected from the completion of the transaction with Sobi and the proceeds from the €30 million capital increase Conference call to be held today at 2:00 p.m. CEST / 8:00 a.m. ET MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its consolidated financial results for th...
17.09.26 - 05:33
Sobi and Innate announce partnership is now effective following completion of closing conditions (PR Newswire)
 
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership with Innate is now effective following the......
14.09.26 - 23:31
Innate Pharma: Fokussierte Pipeline und entscheidende Studiendaten im Blick (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.09.26 - 07:03
Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update (Business Wire)
 
MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST / 8:00 a.m. EDT, to provide a business update for the first half of 2026. Participants in the call will be: Jonathan Dickinson, Chief Executive Officer Markus Jensen, Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice President, Chief Financial Officer Event Details Date and time: September 17, 2026, at 2:00 p.m. CEST / 8:00 a.m. EDT Webcast link: Click here Conference call link: Click here This information is also available on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage ...
02.09.26 - 07:03
Innate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (Business Wire)
 
MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in a fireside chat and one-on-one investor meetings at the following conference: H.C. Wainwright 28th Annual Global Investment Conference Dates: September 14–16, 2026 Location: New York, United States Fireside chat: Date: September 14, 2026 Time: 4:30 PM EDT / 10:30 PM CEST Webcast: Access the webcast The link to access the live webcast of the fireside chat will also be available on the Events page of the Investors section of Innate Pharma's website. A replay will be available following the event. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise in antibody engineering and innovative targ...
10.08.26 - 09:36
Sobi, Innate Join To Conduct TELLOMAK-3 Phase 3 Confirmatory Trial In Cutaneous T-cell Lymphoma (AFX)
 
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Swedish Orphan Biovitrum AB (SOBI.ST) and Innate Pharma (IPHA, IPH, IPH.PA) have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirm......
10.08.26 - 08:39
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma (PR Newswire)
 
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory......
10.08.26 - 08:39
Innate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical Officer (Business Wire)
 
Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome Markus Jensen appointed Chief Medical Officer, bringing leadership continuity to execute TELLOMAK-3 and to prepare for upcoming IPH4502 development milestones MARSEILLE, France--(BUSINESS WIRE)--$IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that, subject to the closing of its strategic partnership with Sobi, it plans to initiate the TELLOMAK-3 confirmatory Phase 3 study of lacutamab in cutaneous T-cell lymphoma (CTCL). Innate also announced the appointment of Markus Jensen as Chief Medical Officer and member of the Executive Leadership Team, effective September 1, 2026, succeeding Sonia Quaratino. The planned initiation of the TELLOMAK-3 confirmatory Phase 3 study marks an important step for Innate as the Company enters a new phase of late-stage clinical an...
10.08.26 - 08:33
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma (PR Newswire)
 
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory......
08.06.26 - 16:57
XETR: Deletion of Instruments from XETRA - 08.06.2026 (XETRA)
 
The following instruments on XETRA do have their last trading day on 08.06.2026. Die folgenden Instrumente auf XETRA haben ihren letzten Handelstag am 08.06.2026. ISIN Name US0028962076 Abercrombie & Fitch Co. US0162551016 Align Technology Inc. US0311001004 AMETEK Inc. US1713401024 Church & Dwight Co. Inc. US1729081059 Cintas Corp. US22052L1044 Corteva Inc. US2310211063 Cummins Inc. US2533931026 Dicks Sporting Goods Inc. US2910111044 Emerson Electric Co. US30212P3038 Expedia Group Inc. FR0004163111 Genfit S.A. US37940X1028 Global Payments Inc. US43300A2033 Hilton Worldwide Holdings Inc. US45168D1046 IDEXX Laboratories Inc. FR0010331421 Innate Pharma S.A. US46266C1053 IQVIA Holdings Inc. US5380341090 Live Nation Entertainment Inc. US5719032022 Marriott International Inc. US57667L1070 Match Group Inc. US5926881054 Mettler-Toledo International Inc. US5950171042 Microchip Technology Inc. US6200763075 Motorola Solutions Inc. US6819191064 Omnicom Group Inc. US68902V1070 Otis Worldwi...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ärger ist nutzlos wie des Meeres Wellen ohne Wind. - Sprichwort China
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!